Leucemia mieloide cronica: un farmaco sperimentale, BMS-354825, efficace nelle forme resistenti o intolleranti all’Imatinib
Nel corso del 46th Annual Meeting of the American Society of Hematology a San Diego, Ricercatori dell’ Howard Hughes Medical Institute ( HHMI ) dell’UCLA ( University of California – Los Angeles ) in ... leggi